Developer docs
API playgroundTry for free, no card

Search company profiles

Philogen

Full company profile

uuid0002ckf

Namestring
Philogen
Legal namestring
Philogen S.p.A.
Websiteurl
philogen.com
Company typeenum
Public
Founded yearint
1996
Descriptiontext

Philogen S.p.A. is a Swiss-Italian clinical-stage biotechnology company founded in 1996 and listed on the Italian Stock Exchange, with operations centered in Sovicille and Monteriggioni (Italy) and a Swiss research subsidiary, Philochem AG. The company develops targeted cancer therapeutics built on three platform technologies: antibody-cytokine fusion proteins (immunocytokines such as L19IL2/Darleukin and L19TNF/Fibromun), DNA-encoded self-assembling chemical libraries for ligand discovery, and small-molecule radiopharmaceutical conjugates (OncoFAP, OncoACP3, OncoCAIX) for imaging and therapy. Its clinical pipeline addresses soft tissue sarcoma, melanoma, prostate cancer, renal cell carcinoma, and additional solid tumor indications, with Nidlegy (a L19IL2/L19TNF combination) at the most advanced regulatory stage.

The business model combines proprietary pipeline development with strategic out-licensing to global pharmaceutical partners. Revenue is generated through upfront payments, development milestones, and royalties rather than direct product sales — the OncoACP3 prostate cancer radiopharmaceutical was licensed to RayzeBio (Bristol-Myers Squibb) in 2025 for a potential value of up to $1.35 billion plus royalties. Long-standing collaborations with Pfizer, Boehringer Ingelheim, AbbVie, and Janssen Biotech underpin the co-development strategy, while two GMP manufacturing sites in Italy support clinical supply and partner needs. The customer base is structurally Big Pharma, with downstream oncology hospitals and patients reached indirectly through partner commercialization.

Financially, the company reported a H2 2025 net profit of EUR 230 million and EUR 380 million in cash reserves, and the most recent fiscal year reflects a steep revenue and earnings inflection consistent with a major milestone-driven event. Co-founders Dario Neri, Giovanni Neri, and Duccio Neri (CEO and President) remain actively engaged, and the scientific leadership has been externally validated through an ERC Advanced Grant and the Swiss Chemical Society's 2026 Industrial Science Award.

Short descriptiontext

Philogen S.p.A. is a Swiss-Italian clinical-stage biotechnology company developing targeted cancer therapeutics — immunocytokines, radiopharmaceuticals, and DNA-encoded library-derived agents — and licensing them to global pharma partners including Bristol-Myers Squibb, Pfizer, AbbVie, and Janssen.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSovicille, Italy
HQ citystring
Sovicille
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted cancer therapeutics, antibody-cytokine fusion proteins, radiopharmaceutical oncology, DNA-encoded chemical libraries, biopharmaceutical licensing
Industry2 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Targeted Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Licensing and Royalties
TypeLicensing Royalties
Description

Philogen generates revenue through licensing agreements with pharmaceutical companies, including upfront payments, milestone payments, and ongoing royalties. Examples include the Pfizer ADC partnership and the RayzeBio/BMS OncoACP3 deal valued at up to $1.35 billion plus royalties.

in.investing.com
2Strategic Research Partnerships
TypeProfessional Services
Description

Revenue from collaborative research agreements with pharmaceutical partners including Boehringer Ingelheim, AbbVie, and Janssen Biotech for co-development of therapeutic candidates.

in.investing.com
3Pipeline Product Development
TypeSubscription Recurring
Description

Development and potential commercialization of proprietary therapeutic candidates including Nidlegy, Fibromun, and other immunocytokine/radiopharmaceutical products targeting cancer.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Philochem
Description

Wholly-owned subsidiary focused on DNA-encoded chemical libraries, radiopharmaceutical research and development, and tumor-targeting diagnostic and therapeutic agents.

philogen.com
Core offering1 text field

Philogen is a clinical-stage biotechnology company that discovers, develops, and manufactures targeted cancer therapeutics based on immunocytokines (antibody-cytokine fusion proteins), DNA-encoded chemical library-derived small molecules, and radiopharmaceuticals. Its pipeline products (Nidlegy, Fibromun, Darleukin, Dodekin, Dekavil, OncoFAP, OncoACP3, OncoCAIX) are developed internally through GMP manufacturing and clinical trials, then monetized via licensing and co-development agreements with global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Fibromun is identified as a key drug candidate in development for soft tissue sarcoma with lung metastases market projected to grow during 2026-2036
+1 more record
Product and service11 records
1Nidlegy
CategoryTargeted Oncology Therapeutic
Description

Immunocytokine product (L19IL2/L19TNF combination) being developed for the treatment of melanoma and other solid tumors; an MAA has been submitted in the European Union.

2Fibromun (L19TNF)
CategoryTargeted Oncology Therapeutic
Description

Antibody-cytokine fusion protein (L19TNF) for the treatment of soft tissue sarcoma with lung metastases and other solid tumors; holds EU Orphan Drug Designation.

3Darleukin (L19IL2)
CategoryTargeted Oncology Therapeutic
Description

Antibody-cytokine fusion protein (L19IL2) used as a targeted immunocytokine therapeutic in Philogen's oncology pipeline, also serving as a component of Nidlegy.

4Dodekin
CategoryTargeted Oncology Therapeutic
Description

Antibody-cytokine fusion protein candidate in Philogen's pipeline targeting tumor-associated antigens for cancer therapy.

5Dekavil
CategoryTargeted Oncology Therapeutic
Description

Targeted therapeutic antibody candidate in Philogen's pipeline for the treatment of inflammatory and oncology indications.

6OncoFAP Radio Conjugates (Imaging)
CategoryRadiopharmaceutical Diagnostic
Description

Small-molecule FAP-targeting radio-conjugate for PET imaging of solid tumors, leveraging Philogen's proprietary OncoFAP ligand.

7OncoFAP Radio Conjugates (Therapy)
CategoryRadiopharmaceutical Therapeutic
Description

Small-molecule FAP-targeting radio-conjugate for radioligand therapy of solid tumors.

8OncoFAP-GlyPro-MMAE (Therapy)
CategoryTargeted Oncology Therapeutic
Description

FAP-targeting antibody-drug conjugate bearing an MMAE payload for targeted chemotherapy of solid tumors.

9OncoACP3 (Imaging)
CategoryRadiopharmaceutical Diagnostic
Description

Radiopharmaceutical diagnostic agent targeting Prostatic Acid Phosphatase (ACP3) for PET imaging of prostate cancer; worldwide rights licensed to RayzeBio/BMS.

10OncoACP3 (Therapy)
CategoryRadiopharmaceutical Therapeutic
Description

Radiopharmaceutical therapeutic agent targeting Prostatic Acid Phosphatase (ACP3) for treatment of prostate cancer; worldwide rights licensed to RayzeBio/BMS.

11OncoCAIX
CategoryRadiopharmaceutical Therapeutic / Diagnostic
Description

Carbonic anhydrase IX (CAIX)-targeting small-molecule agent for imaging and therapy of renal cell carcinoma (kidney cancer).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-06-10
Description

Philochem AG (Philogen subsidiary) licensed worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio, a Bristol-Myers Squibb company. Deal potential value of up to $1.35 billion plus royalties. Antitrust clearance completed and agreement closed in August 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-08-03
Description

Philogen S.p.A. entered into collaboration, option and license agreement with Janssen Biotech for therapeutic development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-02-15
Description

Philogen announced expanded research and development agreement with AbbVie for continued collaboration on therapeutic development.

4Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-10-12
Description

Philogen signed collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute Myeloid Leukemia (AML).

philogen.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-12-22
Description

Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates (ADCs) and targeted nanoparticles. In January 2016, Pfizer exercised options granted under this agreement for potential development and commercialization of multiple ADCs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owns Pluvicto and Lutathera, the most commercially successful targeted radiopharmaceuticals in oncology. While a broad incumbent, Novartis's radioligand franchise defines the commercial benchmark Philogen's programs must compete against.

TypeDirect peer
Description

US radiopharmaceutical company with both diagnostic imaging agents (e.g., PYLARIFY for PSMA) and a growing radiotherapeutic pipeline, closely comparable to Philogen's combined imaging + therapy radiopharma model.

TypeEmerging player
Description

Swiss-listed clinical-stage biotech focused on antibody-drug conjugates for hematologic and solid tumors. Comparable emerging biologics developer with similar partnership-driven monetization and pipeline breadth.

TypeDirect peer
Description

Australian-headquartered radiopharmaceutical company developing targeted imaging and therapy agents for cancer (including prostate cancer PSMA imaging), the most direct comparability to Philogen's OncoACP3 and OncoFAP programs in oncology radiopharmaceuticals.

TypeDirect peer
Description

Global radiopharmaceutical company producing diagnostic and therapeutic radioisotope products across oncology, neurology and cardiology. Direct peer in scale and product category to Philogen's radiopharma business.

TypeRegional player
Description

Italian-headquartered diagnostic imaging company with a strong radiopharmaceutical and contrast imaging portfolio. Direct regional overlap with Philogen in Italian clinical and imaging markets, and competes for similar talent and clinical sites.

TypeEmerging player
Description

Swiss clinical-stage biotech developing DARPin-based targeted cancer therapeutics. Comparable as a Swiss-headquartered, partnership-driven oncology biologics developer with similar size and capital profile.

TypeBroad incumbent
Description

Operates a radiopharmaceutical business (including Xofigo and ongoing pipeline) and has an established oncology therapeutics franchise. As a broad incumbent, it competes for the same pharma partners and licensing counterparties that Philogen targets.

TypeDirect peer
Description

German radiopharmaceutical company developing targeted radionuclide therapies and diagnostics for cancer. Comparable in modality, target indications, and licensing-led go-to-market to Philogen's radiopharma pipeline.

TypeOthers
Description

Drug discovery company specializing in DNA-encoded library screening for hit identification, closely analogous to Philogen's DEL-based discovery engine. Comparable as an enabling technology vendor / partner in the DEL ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Philogen

Targeted Oncology Biopharmaceuticalsphilogen.com

Philogen S.p.A. is a Swiss-Italian clinical-stage biotechnology company developing targeted cancer therapeutics — immunocytokines, radiopharmaceuticals, and DNA-encoded library-derived agents — and licensing them to global pharma partners including Bristol-Myers Squibb, Pfizer, AbbVie, and Janssen.

What Philogen does

Philogen S.p.A. is a Swiss-Italian clinical-stage biotechnology company founded in 1996 and listed on the Italian Stock Exchange, with operations centered in Sovicille and Monteriggioni (Italy) and a Swiss research subsidiary, Philochem AG. The company develops targeted cancer therapeutics built on three platform technologies: antibody-cytokine fusion proteins (immunocytokines such as L19IL2/Darleukin and L19TNF/Fibromun), DNA-encoded self-assembling chemical libraries for ligand discovery, and small-molecule radiopharmaceutical conjugates (OncoFAP, OncoACP3, OncoCAIX) for imaging and therapy. Its clinical pipeline addresses soft tissue sarcoma, melanoma, prostate cancer, renal cell carcinoma, and additional solid tumor indications, with Nidlegy (a L19IL2/L19TNF combination) at the most advanced regulatory stage.

The business model combines proprietary pipeline development with strategic out-licensing to global pharmaceutical partners. Revenue is generated through upfront payments, development milestones, and royalties rather than direct product sales — the OncoACP3 prostate cancer radiopharmaceutical was licensed to RayzeBio (Bristol-Myers Squibb) in 2025 for a potential value of up to $1.35 billion plus royalties. Long-standing collaborations with Pfizer, Boehringer Ingelheim, AbbVie, and Janssen Biotech underpin the co-development strategy, while two GMP manufacturing sites in Italy support clinical supply and partner needs. The customer base is structurally Big Pharma, with downstream oncology hospitals and patients reached indirectly through partner commercialization.

Financially, the company reported a H2 2025 net profit of EUR 230 million and EUR 380 million in cash reserves, and the most recent fiscal year reflects a steep revenue and earnings inflection consistent with a major milestone-driven event. Co-founders Dario Neri, Giovanni Neri, and Duccio Neri (CEO and President) remain actively engaged, and the scientific leadership has been externally validated through an ERC Advanced Grant and the Swiss Chemical Society's 2026 Industrial Science Award.

Philogen firmographics

Firmographics
Name
Philogen
Legal name
Philogen S.p.A.
Website
https://philogen.com
Company type
Public
Founded year
1996
Operating status
Operating
Headcount range
101–250 employees
Short description
Philogen S.p.A. is a Swiss-Italian clinical-stage biotechnology company developing targeted cancer therapeutics — immunocytokines, radiopharmaceuticals, and DNA-encoded library-derived agents — and licensing them to global pharma partners including Bristol-Myers Squibb, Pfizer, AbbVie, and Janssen.
Ownership category
akta.pro rank

Philogen industry classification

Industry
Product category
Targeted Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Targeted cancer therapeutics
  • Antibody-cytokine fusion proteins
  • Radiopharmaceutical oncology
  • DNA-encoded chemical libraries
  • Biopharmaceutical licensing

Where Philogen is headquartered

Location

Headquarters

HQ city
Sovicille
HQ country
Italy
HQ region
Europe

Offices3 records

Markets served

Philogen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Licensing and Royalties: Philogen generates revenue through licensing agreements with pharmaceutical companies, including upfront payments, milestone payments, and ongoing royalties. Examples include the Pfizer ADC partnership and the RayzeBio/BMS OncoACP3 deal valued at up to $1.35 billion plus royalties.
  2. Strategic Research Partnerships: Revenue from collaborative research agreements with pharmaceutical partners including Boehringer Ingelheim, AbbVie, and Janssen Biotech for co-development of therapeutic candidates.
  3. Pipeline Product Development: Development and potential commercialization of proprietary therapeutic candidates including Nidlegy, Fibromun, and other immunocytokine/radiopharmaceutical products targeting cancer.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Philogen product offering

Product offering

Core offering

Philogen is a clinical-stage biotechnology company that discovers, develops, and manufactures targeted cancer therapeutics based on immunocytokines (antibody-cytokine fusion proteins), DNA-encoded chemical library-derived small molecules, and radiopharmaceuticals. Its pipeline products (Nidlegy, Fibromun, Darleukin, Dodekin, Dekavil, OncoFAP, OncoACP3, OncoCAIX) are developed internally through GMP manufacturing and clinical trials, then monetized via licensing and co-development agreements with global pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

  • Philochem: Wholly-owned subsidiary focused on DNA-encoded chemical libraries, radiopharmaceutical research and development, and tumor-targeting diagnostic and therapeutic agents.

Products and services

  • Nidlegy Immunocytokine product (L19IL2/L19TNF combination) being developed for the treatment of melanoma and other solid tumors; an MAA has been submitted in the European Union.
  • Fibromun (L19TNF) Antibody-cytokine fusion protein (L19TNF) for the treatment of soft tissue sarcoma with lung metastases and other solid tumors; holds EU Orphan Drug Designation.
  • Darleukin (L19IL2) Antibody-cytokine fusion protein (L19IL2) used as a targeted immunocytokine therapeutic in Philogen's oncology pipeline, also serving as a component of Nidlegy.
  • Dodekin Antibody-cytokine fusion protein candidate in Philogen's pipeline targeting tumor-associated antigens for cancer therapy.
  • Dekavil Targeted therapeutic antibody candidate in Philogen's pipeline for the treatment of inflammatory and oncology indications.
  • OncoFAP Radio Conjugates (Imaging) Small-molecule FAP-targeting radio-conjugate for PET imaging of solid tumors, leveraging Philogen's proprietary OncoFAP ligand.
  • OncoFAP Radio Conjugates (Therapy) Small-molecule FAP-targeting radio-conjugate for radioligand therapy of solid tumors.
  • OncoFAP-GlyPro-MMAE (Therapy) FAP-targeting antibody-drug conjugate bearing an MMAE payload for targeted chemotherapy of solid tumors.
  • OncoACP3 (Imaging) Radiopharmaceutical diagnostic agent targeting Prostatic Acid Phosphatase (ACP3) for PET imaging of prostate cancer; worldwide rights licensed to RayzeBio/BMS.
  • OncoACP3 (Therapy) Radiopharmaceutical therapeutic agent targeting Prostatic Acid Phosphatase (ACP3) for treatment of prostate cancer; worldwide rights licensed to RayzeBio/BMS.
  • OncoCAIX Carbonic anhydrase IX (CAIX)-targeting small-molecule agent for imaging and therapy of renal cell carcinoma (kidney cancer).

Quantifiable outcome

  • Fibromun is identified as a key drug candidate in development for soft tissue sarcoma with lung metastases market projected to grow during 2026-2036
  • +1 more outcomes

Companies that use Philogen

Customer profile

Segments2 records

Ideal customer profiles3 records

Philogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Philogen partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • RayzeBio (Bristol-Myers Squibb)coreOEM/ Whitelabel/ Licensing Partner · 10 June 2025Philochem AG (Philogen subsidiary) licensed worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio, a Bristol-Myers Squibb company. Deal potential value of up to $1.35 billion plus royalties. Antitrust clearance completed and agreement closed in August 2025.
  • Janssen BiotechcoreStrategic or Co-development Partner · 3 August 2016Philogen S.p.A. entered into collaboration, option and license agreement with Janssen Biotech for therapeutic development.
  • AbbViecoreStrategic or Co-development Partner · 15 February 2016Philogen announced expanded research and development agreement with AbbVie for continued collaboration on therapeutic development.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 12 October 2015Philogen signed collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute Myeloid Leukemia (AML).
  • PfizercoreTechnology or Integration · 22 December 2014Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates (ADCs) and targeted nanoparticles. In January 2016, Pfizer exercised options granted under this agreement for potential development and commercialization of multiple ADCs.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Philogen competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Owns Pluvicto and Lutathera, the most commercially successful targeted radiopharmaceuticals in oncology. While a broad incumbent, Novartis's radioligand franchise defines the commercial benchmark Philogen's programs must compete against.
  • Bayer: Operates a radiopharmaceutical business (including Xofigo and ongoing pipeline) and has an established oncology therapeutics franchise. As a broad incumbent, it competes for the same pharma partners and licensing counterparties that Philogen targets.

Direct peers

  • Lantheus Holdings: US radiopharmaceutical company with both diagnostic imaging agents (e.g., PYLARIFY for PSMA) and a growing radiotherapeutic pipeline, closely comparable to Philogen's combined imaging + therapy radiopharma model.
  • Telix Pharmaceuticals: Australian-headquartered radiopharmaceutical company developing targeted imaging and therapy agents for cancer (including prostate cancer PSMA imaging), the most direct comparability to Philogen's OncoACP3 and OncoFAP programs in oncology radiopharmaceuticals.
  • Curium Pharma: Global radiopharmaceutical company producing diagnostic and therapeutic radioisotope products across oncology, neurology and cardiology. Direct peer in scale and product category to Philogen's radiopharma business.
  • ITM Isotope Technologies Munich: German radiopharmaceutical company developing targeted radionuclide therapies and diagnostics for cancer. Comparable in modality, target indications, and licensing-led go-to-market to Philogen's radiopharma pipeline.

Emerging players

  • ADC Therapeutics: Swiss-listed clinical-stage biotech focused on antibody-drug conjugates for hematologic and solid tumors. Comparable emerging biologics developer with similar partnership-driven monetization and pipeline breadth.
  • Molecular Partners: Swiss clinical-stage biotech developing DARPin-based targeted cancer therapeutics. Comparable as a Swiss-headquartered, partnership-driven oncology biologics developer with similar size and capital profile.

Regional players

  • Bracco Imaging: Italian-headquartered diagnostic imaging company with a strong radiopharmaceutical and contrast imaging portfolio. Direct regional overlap with Philogen in Italian clinical and imaging markets, and competes for similar talent and clinical sites.

Others

  • X-Chem: Drug discovery company specializing in DNA-encoded library screening for hit identification, closely analogous to Philogen's DEL-based discovery engine. Comparable as an enabling technology vendor / partner in the DEL ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Philogen social profiles

Digital presence

Philogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Philogen leadership team

Management profile

Number of profiles

Profiles5 records

Philogen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Philogen funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Philogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Philogen

What does Philogen do?

Philogen is a clinical-stage biotechnology company that discovers, develops, and manufactures targeted cancer therapeutics based on immunocytokines (antibody-cytokine fusion proteins), DNA-encoded chemical library-derived small molecules, and radiopharmaceuticals. Its pipeline products (Nidlegy, Fibromun, Darleukin, Dodekin, Dekavil, OncoFAP, OncoACP3, OncoCAIX) are developed internally through GMP manufacturing and clinical trials, then monetized via licensing and co-development agreements with global pharmaceutical partners.

Is Philogen a public or private company?

Philogen is a public company. It is classified as public and is currently operating.

When was Philogen founded?

Philogen was founded in 1996. It employs 101 to 250 people.

Where is Philogen based?

Philogen is headquartered in Sovicille, Italy, in the Europe region.

How does Philogen make money?

Three revenue lines are on record. Pharmaceutical Licensing and Royalties are the primary driver. The others are strategic Research Partnerships and pipeline Product Development.

Who are Philogen's main competitors?

Broad incumbents on record are Novartis and Bayer. Direct peers are Lantheus Holdings, Telix Pharmaceuticals, Curium Pharma and ITM Isotope Technologies Munich. Emerging players are ADC Therapeutics and Molecular Partners. Bracco Imaging is listed as a regional player. X-Chem is listed as an others.

Does Philogen have an API?

No public API is recorded for Philogen.

What industry is Philogen in?

Philogen's product category is Targeted Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEarnings Call Transcripts - Investing.comPhilogen reported first-half 2026 cash reserves above EUR 300 million, up from EUR 100 million a year earlier, while posting an EBITDA loss of about EUR 20 million. The company remains in development-stage losses and expects future revenue from existing contracts and milestone payments, with no specific H2 guidance.ScanXPhilogen resubmits Nidlegy EMA application with 33-month follow-up dataItalian biotech company Philogen resubmitted its Marketing Authorization Application for Nidlegy to the European Medicines Agency on July 27, 2026, seeking approval for neoadjuvant treatment of locally advanced melanoma. The updated application includes 33 months of follow-up data from the Phase III PIVOTAL study demonstrating reduced relapse risk and addresses previous Chemistry, Manufacturing and Controls queries. Sun Pharmaceutical holds partnership rights for the therapy across Europe, Australia, and New Zealand.PR NewswireSoft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsightThe soft tissue sarcoma market in the 7MM is projected to grow at a CAGR of 7.9% from 2026 to 2036, with the market size at USD 310 million in 2025. The United States accounted for approximately 85% of the total market size in 2025, and the incidence is expected to rise through 2036.PR NewswireSoft Tissue Sarcoma with Lung Metastases Market Set to Expand Across the 7MM During the Forecast Period (2026-2036) with Advancing Targeted and Cellular Therapies | DelveInsightDelveInsight published a market research report projecting the soft tissue sarcoma with lung metastases treatment market across the 7 major markets (US, EU4, UK, Japan) to grow steadily during the 2026–2036 forecast period, driven by anticipated launches of novel therapies. The report identifies several drug candidates in development including Annamycin (Moleculin), IP-001 (Immunophotonics), Fibromun (Philogen), Lifileucel (Iovance Biotherapeutics), and Chiauranib (Chipscreen). The US held the largest market share in 2025, with approximately 14,000 new soft tissue sarcoma cases diagnosed annually and up to 50% of patients eventually developing lung metastases.PharmTechThe Future of Downstream ProcessingThis article examines the growing bottleneck in downstream processing within the biopharmaceutical industry, where capacity has failed to keep pace with upstream production improvements that have increased protein titers to over 10 grams per liter. The author, Uwe Gottschalk of Sartorius Stedim Biotech, outlines three approaches manufacturers are pursuing: streamlining existing processes using quality-by-design principles, adopting simpler technologies from the bulk-chemical industry such as precipitation and crystallization, and implementing innovative technologies including membrane chromatography and disposable modules. Specific examples cited include Pfizer's process redesign that reduced processing time by over 45% and Philogen's successful use of membrane absorbers achieving 90% recovery and 99.9% purity, with the author concluding that the future of bioprocessing will depend more on innovation and flexibility than on traditional large-scale facilities.Investing.comEarnings call transcript: Philogen’s H2 2025 highlights strong financials and product innovation By Investing.comPhilogen SpA reported strong financial results for 2025 with net profit of EUR 230 million and cash reserves of EUR 380 million, while also detailing significant clinical pipeline progress including planned EMA resubmission for Nidlegy in July 2026 for melanoma treatment. The company disclosed mixed clinical trial outcomes with Fibromun showing survival signals in first-line soft tissue sarcoma patients but failing to meet primary endpoints in second-line glioblastoma and third-line STS. Strategic partnerships remain key to growth, including the OncoACP3 deal with Bristol Myers Squibb/RayzeBio and ongoing collaboration with Sun Pharma for Fibromun commercialization.GlobeNewswirePhilogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent AuthoritiesPhilogen S.p.A. announced that its new GMP facility in Rosia, Italy, received certification from AIFA after a July 2023 inspection. The facility, costing over €15 million, will produce therapeutic proteins like Nidlegy™ for clinical and commercial use. The company plans to supply commercial supplies of Nidlegy™ from the site.MarketScreenerPhilogen purchased more than 6,200 shares of its own common stockPhilogen Spa purchased 6,294 of its own ordinary shares between Sept. 4 and Sept. 8 at an average price of EUR16.4642, totaling EUR103,625.46. The company holds 282,021 shares, representing 0.7% of its share capital, and its stock is flat at EUR16.00 per share.MarketScreenerPhilogen purchased more than 7,800 shares of its own common stockPhilogen Spa purchased 7,837 of its own ordinary shares between Aug. 21 and Aug. 25 at an average price of EUR16.3757, totaling EUR128,336.70. The company now holds 268,314 shares, representing 0.7% of its share capital. Its stock rose 1.9% to EUR16.50 on Monday.